Document Classification

Section Type: RESULTS

Text: However, in preplanned analyses, overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials : in LUX-Lung 3, median overall survival was 33. 3 months (95 % CI 26. 8-41. 5) in the afatinib group versus 21. 1 months (16. 3-30. 7) in the chemotherapy group (HR 0. 54, 95 % CI 0. 36-0. 79, p = 0. 0015) ; in LUX-Lung 6, it was 31. 4 months (95 % CI 24. 2-35. 3) versus 18. 4 months (14. 6-25. 6), respectively (HR 0. 64, 95 % CI 0. 44-0. 94, p = 0. 023).